In obesity settings, the inhibition of endogenous GIP or its receptor leads to negative energy balance and reduced adiposity, and paradoxically, a similar effect is obtained after administration of exogenous GIP agonists. The gene discussed is GIP; the disease is obesity due to melanocortin 4 receptor deficiency.